The first Dengue vaccine Phase-3 clinical trial in India is done with which indigenous Dengue vaccine in August 2024?

Correct option is C

The correct answer is (c) DengiAll

Explanation: (Information about the correct answer):
. DengiAll is the first indigenous Dengue vaccine to enter Phase-3 clinical trials in India in August 2024.
. It has been developed by Panacea Biotec in collaboration with ICMR–National Institute of Virology (NIV), Pune.
. The vaccine is a tetravalent Dengue vaccine, designed to protect against all four Dengue virus serotypes (DEN-1 to DEN-4).
. Phase-3 trials mark a crucial step before large-scale approval and public use.
. This trial represents a major milestone in India’s self-reliance in vaccine development.

Information Booster: (additional info around the correct answer):
. Dengue is a vector-borne viral disease transmitted by Aedes aegypti mosquitoes.
. India reports millions of Dengue cases annually, making vaccine development a public-health priority.

Additional Knowledge: (Information about incorrect options):

Dengisure (Option a)
. Dengisure is not associated with India’s first Phase-3 Dengue vaccine trial.
. It is not an approved or widely recognized indigenous Dengue vaccine.

Dengvax (Option b)
. Dengvaxia is developed by Sanofi (France) and is not indigenous to India.
. Its use is restricted due to safety concerns in Dengue-naïve individuals.

D-Vax Plus (Option d)
. D-Vax Plus is not the vaccine used in the Phase-3 trial conducted in August 2024.
. It does not have confirmed large-scale clinical trial approval in India.